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Clinically there are several different types of eosinophilic pneumonia (EP), but other than
for tropical pulmonary eosinophilia, the humoral immune response between different
types of EP, such as acute eosinophilic pneumonia (AEP), chronic EP, drug-induced EP,
allergic bronchopulmonary aspergillosis, and Churg–Strauss syndrome, has not been
examined. Immunoglobulin G (IgG) and E (IgE) serum concentrations were analyzed in
patients with EP, or bacterial pneumonia, and in age-matched controls. Patients with AEP
had lower IgG levels than the age-matched controls. Serum IgG levels in patients with AEP
were significantly lower than in patients with other types EP or bacterial pneumonia. IgG2
and IgG4 were also significantly decreased in AEP, compared to age-matched controls. In
AEP, the serum IgG levels were significantly decreased during active disease and increased
during remission, but the serum IgE levels did not change significantly, indicating a
decrease in serum IgG is a common feature of AEP. Low IgG levels were significantly
correlated with serum surfactant protein D and absolute eosinophil counts in the
bronchoalveolar lavage fluid of patients with AEP. This is the first reported study of
immunoglobulin levels in AEP. The pathogenesis of AEP might negatively affect serum IgG
levels, but not IgE levels. The present findings might indicate that serum IgG reflects the
inflammatory response in AEP.
& 2008 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Eosinophilic pneumonia (EP) is defined as the pulmonary
infiltration of eosinophils independent of peripheral blood
eosinophilia. This pulmonary disorder includes clinically
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pneumonia (AEP), chronic eosinophilic pneumonia (CEP),
drug-induced eosinophilic pneumonia (drug-EP), allergic
bronchopulmonary mycosis (ABPM), and Churg–Strauss syn-
drome (CSS). Although there are a few reports comparing
the clinical characteristics of these different forms of EP,1–4
there are no reports describing the pathogenesis of these
different forms.
Serum immunoglobulin G (IgG), IgA, IgM, and IgE are
elevated in tropical pulmonary eosinophilia (TPE) 5,6 and EP7
during peak disease activity. Thereafter, the serum immu-
noglobulin levels return to normal during disease resolu-
tion.5–7 In contrast to TPE, serum IgG is decreased in AEP
during peak disease activity and increased during resolution.
The serum levels of surfactant protein A (SP-A), SP-D, and
KL-6 are useful biomarkers and prognostic factors for
interstitial pneumonia.8 Destruction of the alveolar epithe-
lium and endothelium might cause hyperlucent blood. A
recent study demonstrated that the serum or bronchoalveo-
lar fluid (BALF) SP-D levels were more sensitive than those of
SP-A and KL-6 in reflecting the inflammatory response in
AEP.9 SP-D is hydrophilic and belongs to the collectin
subgroup of the C-type lectin superfamily.10 SP-D molecules
are very specific and are produced only in the lung by two
types of epithelial cells, clara and alveolar type II cells.11 We
present here negative correlations between serum SP-D and
IgG. The findings reported in the present study are the first
to demonstrate that IgG levels are decreased in AEP.Method
Patients
Patient backgrounds are summarized in Table 1. The 40
patients with EP (eight with AEP, nine with CEP, nine with
drug-EP, eight with ABPM, and six with CSS) were diagnosed
at the Oita University Faculty of Medicine Hospital and
related hospitals from 2000–2006. The seven of eight
patients with AEP were smoking-induced AEP. Pulmonary
eosinophilia was detected by bronchoalveolar lavage (BAL)
and transbronchial lung biopsy specimens. AEP was diag-
nosed according to the modified Allen’s criteria.12 In
contrast to previous reports, patients with AEP often show
spontaneous resolution in Japan.9 Most patients with AEPTable 1 Subject characteristics.
AEP CEP Drug-EP
Sex (M/F) (6/2) (3/6) (6/3)
Age 20.8671.47 56.0072.57 65.4472
BAL total cells ( 105/ml) 7.0771.24 12.9773.46 5.4771
Eo (%) 59.7875.99 57.8176.35 33.1072
Lym (%) 14.873.00 9.9375.59 18.2374
Neut (%) 5.7074.11 4.2772.92 9.0674
CD4/8 2.0270.374 2.6170.32 1.5370
Definition of abbreviation: AEP, acute eosinophilic pneumonia; CEP, c
eosinophilic pneumonia; ABPM, allergic bronchopulmonary mycosis; C
pneumonia; HV, healthy volunteers.
Data are expressed as mean7SEM.improved spontaneously, although two patients required
corticosteroid therapy for a few days. The diagnosis of CEP
was made based on the diagnostic criteria of CEP described
by Carrington et al.13 All patients were treated with
corticosteroids. The patients with drug-EP satisfied the
following diagnostic criteria: fever or some respiratory
symptoms, diffuse pulmonary infiltrates on chest X-ray
films, increased percentage of eosinophils in BALF, prompt
improvement after cessation of the causative drug, absence
of other possible causes, positive reaction in lymphocyte
stimulation assays, or recurrence of the symptoms with a
drug challenge. Allergic bronchopulmonary aspergillosis is
also referred to as ABPM. ABPM was diagnosed according to
the modified Greenberg and Petterson criteria.14,15 The
diagnosis of CSS was made according to the 1990 edition of
CSS published by the American College of Rheumatology.16
We also studied a control group of 26 patients with non-
eosinophilic lung disease; seven patients with bacterial and
atypical pneumonia (pneumonia), 19 healthy volunteers
(HV). All tests were performed in the context of routine
medical care of the patients. None of the patients was
treated with glucocorticoids before the BAL procedures
were completed. Written informed consent was provided by
the HV.
BAL
BAL was performed in an affected lung segment using three
50-ml aliquots of saline solution. The differential cell count
was determined by cytocentrifugation followed by Wright
staining. Fluid samples were processed immediately for
cytologic and microbiologic analysis. No organisms were
cultured from the BAL culture. Cytology was negative for
malignant cells.
Determination of serum IgG, IgG subclass, IgE, and
SP-D
Routine laboratory tests were performed in all cases at the
diagnosis. IgG, IgG subclass, IgE, and SP-D concentrations in
the serum were measured by SRL, Inc. (Tokyo, Japan) before
starting steroid therapy. The reference ranges were
8.7–17.0 g/l (IgG), less than 170 IU/ml (IgE), and 110 ng/ml
(SP-D).ABPM CSS Pneumonia HV
(2/6) (1/5) (2/5) (7/12)
.32 56.3871.69 56.3371.34 56.2577.86 19.8473.30
.90 4.5070.52 10.1473.39 N.D N.D
.52 41.27712.01 61.00720.79 N.D N.D
.48 9.4572.98 3.5771.27 N.D N.D
.81 7.0573.02 0.370.3 N.D N.D
.52 4.4172.50 2.2070.29 N.D N.D
hronic idiopathic eosinophilic pneumonia; drug-EP, drug-induced
SS, Churg–Strauss syndrome; bacterial and atypical pneumonia,
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The Kruskal–Wallis test was used to compare values between
groups. In case of a significant difference between groups,
data were further analyzed by Mann–Whitney U-test. Correla-
tion coefficients were determined by Pearson’s linear regres-
sion analysis between IgG, SP-D, and absolute eosinophil
counts in BAL. Significant differences between active disease
and resolution of the disease were determined by paired t-test
or Wilcoxon signed ranks test. A difference was considered
significant when the P-value was less than 0.05.
Results
Serum IgG and IgE concentrations in various diffuse
lung diseases
IgG concentrations were significantly decreased in AEP
(P ¼ 0.0041), compared to aged-match HV (Figure 1a).
There was a significant difference in serum IgG concentra-
tions between different types of EP, including bacterial
pneumonia (Figure 1b). IgG2 and IgG4 were significantly
decreased in AEP, compared to age-match HV (Figure 2). In
contrast to these findings, there was no significant differ-
ence in serum IgA, IgM, and IgE concentrations between
different EP types (data not shown).
Relationship between serum IgG, and serum SP-D,
and cell analysis in BALF
There was a significant negative correlation between IgG
and SP-D concentrations in the serum from patients with AEP10
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Figure 1 (a) Serum IgG levels obtained from patients with acut
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with acute eosinophilic pneumonia (AEP), chronic eosinophilic p
bronchopulmonary mycosis (ABPM), Churg–Strauss syndrome (CSS),
Gray bar indicates the IgG reference range.(P ¼ 0.00179; Figure 3a). There was also a significant
positive correlation between the serum IgG and absolute
eosinophil counts in BAL from patients with AEP (P ¼ 0.0063;
Figure 3b). There were no correlation between SP-D and
serum IgG in other classifications of pulmonary eosinophilia.
There were also no significant correlation between the serum
IgG and absolute eosinophil counts in BAL from patients with
other classifications of pulmonary eosinophilia.
Serial changes in serum IgG and IgE concentrations
in patients with AEP in the active and recovery
phases
We could measure only four serum samples of IgG
concentration in resolution phase of AEP, because four
patient’s serum of resolution phase were not stocked. The
resolution phase was 1–2 weeks after admission. The
deceased IgG levels were significantly elevated during
resolution. In all but one case, IgE levels were elevated in
patients with AEP. The IgE levels did not change before or
after recovery.
Discussion
Though there have been previous studies of serum immu-
noglobulins (IgG, IgA, IgM, and IgE) in TPE5,6 and EP,7 ours is
the first report on circulating immunoglobulins and IgG
subclass in AEP. Patients with systemic signs of ongoing
inflammation had chronically increased levels of total IgG.
Ray and Saha5 reported that serum IgM and IgE levels were
significantly elevated in TPE, but the changes in serum IgA
and IgG were not significant. In contrast, Sharma et al.6CE
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Figure 2 Serum IgG subclass levels obtained from patients acute eosinophilic pneumonia (n ¼ 5) and healthy volunteer (n ¼ 10).
O. Matsuno et al.902reported that serum IgG, IgA, and IgM were significantly
increased in TPE. McEvoy et al.7 also reported high levels of
IgE and elevated IgG during peak disease activity in EP.
Thereafter, serum immunoglobulins levels fell to normal
during disease resolution.6,7 IgG levels, however, are
modestly decreased in eosinophilic lung disease, such as
relapsing TPE.5 The present study showed that serum IgG
levels were significantly decreased in AEP patients as
compared with those in HV and patients with other types
of EP, but serum IgA, IgM, and IgE levels did not differ
significantly among the EP types. In addition, we also
observed significantly increased levels of IgG during disease
resolution. IgG2 and IgG4 were significantly decreased in
AEP patients, compared to HV. These mechanisms respon-
sible for total IgG reduction are not entirely clear. These
findings seem to correlate the severity with the humoral
immunity in AEP.
The molecular background of IgG decrease is not well
understood. Several Japanese patients with AEP were young
and had a high incidence of short-term smoking history,17,18
although there has been no evidence that a genetic aspect is
related to AEP. In the other, long-term smoking can suppress
humoral immunity. Serum IgG levels were lower in smokers
than non-smokers.19–21 There is, however, no report that
short-term history of smoking is related to suppression of
humoral immunity. There have been other reports linking
decreased immunoglobulins with pulmonary disease (bucil-
lamin-induced pneumonia).22 Whether consumption or
leakage of immunoglobulin has a role in the pathogenesis
of acute hypersensitivity or cytotoxicity, or is in an
independent epiphenomenon, is not clear.The presence of a mild degree of humoral immunodefi-
ciency relates to serum SP-D levels in AEP. Serum SP-D
levels are more sensitive than SP-A and KL-6 levels for
indicating an inflammatory response in AEP.9 SP-D is an
important innate immune molecule that uses both
innate and adaptive immune pathways to effectively
enhance the clearance of pathogens. The relation between
the reduction of IgG and serum SP-D in AEP is not clear.
SP-D also alters cellular immunity such as the inhibitory
effect of SP-D on interleukin-2-dependent T cell prolifera-
tion.23 The effect of SP-D on B cell activation, however, is
not known.
In all but one patient case, IgE were elevated in AEP.
Serum IgE levels did not change during the active and
resolution phases, whereas IgG levels decreased during peak
disease activity and increased during resolution. The
pathogenesis of AEP might negatively affect serum IgG
levels, but not IgE levels.
There are significant correlations between absolute
eosinophil counts in the BALF and serum IgG levels in
patients with AEP. No such relationship was demonstrated
for the absolute numbers or percentages of any other cell
type. Due to a general lack of clear cut and easy to use
serologic markers for the diagnosis and management of AEP,
novel indicators are highly desirable. The results of the
present study suggest that IgG levels are helpful to
distinguish AEP from other types of EP in the early phase
and for evaluating disease activity. Our study is too small
and the duration too short, however, to provide a conclu-
sion. Larger and longer studies addressing this issue are
warranted to judge the diagnostic value.
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Figure 3 Relationship between IgG and SP-D in serum from
patients with AEP (P ¼ 0.0063, r2 ¼ 0.738) (a). Relationship
between serum IgG and absolute eosinophil counts (AEC) in
BALF from patients with AEP (P ¼ 0.0179, r2 ¼ 0.635)(b).
Immunoglobulin levels in acute eosinophilic pneumonia 903Conflict of interest statement
None.
Acknowledgment
The authors are grateful to Kiyoshi Ono for technical
assistance.
References
1. Hayakawa H, Sato A, Toyoshima M, et al. A clinical study of
idiopathic eosinophilic pneumonia. Chest 1994;105:1462–6.
2. Fujimura M, Yasui M, Shinagawa S, et al. Bronchoalveolar lavage
cell findings in three types of eosinophilic pneumonia: acute,
chronic and drug-induced eosinophilic pneumonia. Respir Med
1998;92:743–9.
3. Nakahara Y, Hayashi S, Fukuno Y, et al. Increased interleukin-5
levels in bronchoalveolar lavage fluid is a major factor for
eosinophil accumulation in acute eosinophilic pneumonia.
Respiration 2001;68:389–95.4. Mochimaru H, Kawamoto M, Fukuda Y, et al. Clinicopathological
differences between acute and chronic eosinophilic pneumonia.
Respirology 2005;10:76–85.
5. Ray D, Saha K. Serum immunoglobulin and complement levels in
tropical pulmonary eosinophilia, and their correlation with
primary and relapsing stage of the illness. Am J Trop Med Hyg
1978;27:503–7.
6. Sharma SK, Pande JN, Khilnani GC, Verma K, Khanna M.
Immunology & pulmonary function abnormalities in tropical
pulmonary eosinophilia. Indian J Med Res 1995;101:98–102.
7. McEvoy JDS, Donald KJ, Edwards RL. Immunoglobulin levels and
electron microscopy in eosinophilic pneumonia. Am J Med
1978;64:529–36.
8. Greene KE, King Jr TE, Kuroki Y, Bucher-Bartelson B, Hunnin-
ghake GW, Newman LS, et al. Serum surfactant proteins-A and -
D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J
2002;19:439–46.
9. Daimon T, Tajima S, Oshikawa K, Bando M, Ohno S, Sugiyama Y.
KL-6 and surfactant proteins A and D in serum and bronchoal-
veolar lavage fluid in patients with acute eosinophilic pneumo-
nia. Intern Med 2005;44:811–7.
10. Day AJ. The C-type carbohydrate recognition domain (CRD)
superfamily. Biochem Soc Trans 1994;22:83–8.
11. Haczku A, Vass G, Kierstein S. Surfactant protein D and asthma.
Clin Exp Allergy 2004;34:1815–8.
12. Cottin V, Cordier JF. Eosinophilic pneumonias. Allergy 2005;60:
841–57.
13. Carrington CB, Addington WW, Goff AM, et al. Chronic
eosinophilic pneumonia. N Engl J Med 1969;10(280):787–98.
14. Rosenberg M, Patterson R, Mintzer R, Cooper BJ, Roberts M,
Harris KE. Clinical and immunologic criteria for the diagnosis of
allergic bronchopulmonary aspergillosis. Ann Intern Med
1977;86:405–14.
15. Greenberger PA, Patterson R. Diagnosis and management of
allergic bronchopulmonary aspergillosis. Ann Allergy 1986;56:
444–8.
16. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP,
et al. The American College of Rheumatology 1990 criteria for
the classification of Churg–Strauss syndrome (allergic granulo-
matosis and angiitis). Arthritis Rheum 1990;33:1094–100.
17. Shintani H, Fujimura M, Ishiura Y, Noto M. A case of cigarette
smoking-induced acute eosinophilic pneumonia showing toler-
ance. Chest 2000;117:277–9.
18. Nakajima M, Manabe T, Sasaki T, Niki Y, Matsushima T. Acute
eosinophilic pneumonia caused by cigarette smoking. Intern
Med 2000;39:1131–2.
19. Gonzalez-Quintela A, Alende R, Gude F, Campos J, Rey J,
Meijide LM, et al. Serum levels of immunoglobulins (IgG, IgA,
IgM) in a general adult population and their relationship with
alcohol consumption, smoking and common metabolic abnorm-
alities. Clin Exp Immunol 2008;151:42–50.
20. Gylle´n P, Andersson BA, Qvarfordt I. Smokeless tobacco or
nicotine replacement therapy has no effect on serum immu-
noglobulin levels. Respir Med 2004;98:108–14.
21. Andersen P, Pedersen OF, Bach B, Bonde GJ. Serum antibodies
and immunoglobulins in smokers and nonsmokers. Clin Exp
Immunol 1982;47:467–73.
22. Inokuma S, Sakata M, Yoshida A, Shiratori K, Kiyosawa H.
Bucillamine induced pulmonary injury occurs with immunoglo-
bulin decrease. J Rheumatol 1996;23:1282–5.
23. Borron PJ, Crouch EC, Lewis JF, Wright JR, Possmayer F, Fraher
LJ. Recombinant rat surfactant-associated protein D inhibits
human T lymphocyte proliferation and IL-2 production.
J Immunol 1998;161:4599–603.
